Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project-Reference-Cited by-同舟云学术

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

Published:2012-10-03 Issue:3 Volume:27 Page:711-717
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Avet-Loiseau H, ,Durie B G M,Cavo M,Attal M,Gutierrez N,Haessler J,Goldschmidt H,Hajek R,Lee J H,Sezer O,Barlogie B,Crowley J,Fonseca R,Testoni N,Ross F,Rajkumar S V,Sonneveld P,Lahuerta J,Moreau P,Morgan G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012282.pdf

Reference29 articles.

1. Durie BG, Salmon SE, Moon TE . Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980; 55: 364–372.

2. Bataille R, Durie BG, Grenier J, Sany J . Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986; 4: 80–87.

3. Bataille R, Durie BG, Grenier J . Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983; 55: 439–447.

4. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A . C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737.

5. Bataille R, Jourdan M, Zhang XG, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–2011.

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07

2. Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature;International Journal of Cancer;2024-06-14

3. Risk stratification in multiple myeloma: Are we there yet?;British Journal of Haematology;2024-04-14

4. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Refractory Multiple Myeloma;2024-01-24

5. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma;Journal of Clinical Oncology;2024-01-01